Inherited Skin Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Inherited Skin Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Inherited skin disorders encompass a diverse group of genetic conditions affecting the skin’s structure, function, or development. These disorders can manifest as a range of symptoms, including abnormalities in pigmentation, texture, or the presence of certain growths or lesions. Examples of inherited skin disorders include epidermolysis bullosa, ichthyosis, and albinism. These conditions often result from mutations in specific genes responsible for skin development and maintenance.
The Inherited Skin Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Inherited Skin Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Inherited Skin Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Inherited Skin Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Inherited Skin Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Inherited Skin Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Inherited Skin Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Azitra IncBiogenera SpA
Clayton Biotechnologies Inc
Daiichi Sankyo Co Ltd
DermaXon LLC
Dominion Minerals Ltd
Inozyme Pharma Inc
Johnson & Johnson
Kamari Pharma Ltd
Krystal Biotech Inc
Neurodon LLC
Novartis AG
Qualix DoT sl
Relief Therapeutics Holding AG
Sol-Gel Technologies Ltd
Timber Pharmaceuticals Inc
Yale University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Inherited Skin Disorders reports